Xconomy Forum: What’s Hot in Boston Biotech

Life sciences innovation is moving fast these days, and perhaps nowhere is this more evident than in Boston. Local companies, researchers, and entrepreneurs are pursuing some of the boldest ideas in the field—T-cell therapy, gene therapy, and microbiome analysis, among others. What’s more, they’re seeing real results, in human trials, that indicate these approaches might soon change the way a number of diseases are treated. But a whole host of hurdles still have to be cleared. How can we avoid the pitfalls of the past, and turn these innovative visions into a reality? What’s it going to take to get new types of treatments approved? And how will we pay for them? Join Xconomy as we bring together a group of Boston biotech’s top innovators, entrepreneurs, investors, and leaders as we explore the brightest spots on the life sciences horizon.

Confirmed Speakers:

David Altshuler
- Executive VP of Global Research and CSO, Vertex Pharmaceuticals
Susan Lindquist
- Member, Whitehead Institute; Scientific Founder, Yumanity Therapeutics
Noubar Afeyan
- Managing Partner and CEO, Flagship Ventures
Alexis Borisy
- Chairman, Foundation Medicine; Partner, Third Rock Ventures
Tony Coles
- CEO, Chairman, and Founding Investor, Yumanity Therapeutics
James Collins
- Termeer Professor of Medical Engineering & Science, MIT
Olivier Danos
- Senior Vice President, Gene Therapy, Biogen Idec
Michelle Dipp
- Co-founder and CEO, OvaScience
Peter Kolchinsky
- Managing Member and Portfolio Manager, RA Capital Management
Adam Koppel
- Senior Vice President and Chief Strategy Officer, Biogen Idec
Marian Nakada
- VP of Venture Investments, Johnson & Johnson Innovation
Amir Nashat
- Managing Partner, Polaris Partners
Bernat Olle
- Principal, PureTech Ventures
Steve Paul
- President and CEO, Voyager Therapeutics
Samantha Singer
- COO, The Broad Institute of MIT and Harvard
Chuck Wilson
- CEO and President, Unum Therapeutics